Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.

Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL.

Am J Epidemiol. 2008 Jun 15;167(12):1407-15. doi: 10.1093/aje/kwn090. Epub 2008 Apr 29.

2.

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL.

JAMA Oncol. 2015 Jun;1(3):296-305. doi: 10.1001/jamaoncol.2015.0494.

PMID:
26181174
3.

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.

Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, Jo O'Sullivan M, Rossouw JE, Anderson GL.

Am J Epidemiol. 2008 May 15;167(10):1207-16. doi: 10.1093/aje/kwn044. Epub 2008 Mar 27.

4.

Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.

Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA.

Arch Intern Med. 2010 Oct 11;170(18):1678-85. doi: 10.1001/archinternmed.2010.342.

5.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

6.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators.

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

7.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S; Women's Health Initiative Steering Committee.

JAMA. 2004 Apr 14;291(14):1701-12.

PMID:
15082697
8.

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT; WHI Investigators.

JAMA. 2006 Apr 12;295(14):1647-57.

PMID:
16609086
9.

Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.

Tang JY, Spaunhurst KM, Chlebowski RT, Wactawski-Wende J, Keiser E, Thomas F, Anderson ML, Zeitouni NC, Larson JC, Stefanick ML.

J Natl Cancer Inst. 2011 Oct 5;103(19):1469-75. doi: 10.1093/jnci/djr333. Epub 2011 Aug 30.

10.

Recent epidemiological evidence relevant to the clinical management of the menopause.

Shapiro S.

Climacteric. 2007 Oct;10 Suppl 2:2-15. Review.

PMID:
17882666
11.

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH; Women's Health Initiative Memory Study.

JAMA. 2004 Jun 23;291(24):2947-58.

PMID:
15213206
12.

Invited commentary: Postmenopausal unopposed estrogen and breast cancer risk in the Women's Health Initiative--before and beyond.

Linet MS.

Am J Epidemiol. 2008 Jun 15;167(12):1416-20. doi: 10.1093/aje/kwn089. Epub 2008 Apr 29.

PMID:
18448443
13.

Menopausal hormone therapy and breast cancer.

Santen RJ.

J Steroid Biochem Mol Biol. 2014 Jul;142:52-61. doi: 10.1016/j.jsbmb.2013.06.010. Epub 2013 Jul 16.

PMID:
23871991
14.

Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.

Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, Lane DS, Johnson KC, Wactawski-Wende J, Chen C, Qi L, Yasmeen S, Newcomb PA, Prentice RL.

J Natl Cancer Inst. 2013 Apr 17;105(8):526-35. doi: 10.1093/jnci/djt043. Epub 2013 Mar 29.

15.

Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index.

Chlebowski RT, Anderson GL, Aragaki AK, Prentice R.

J Natl Cancer Inst. 2015 Nov 5;108(2). pii: djv327. doi: 10.1093/jnci/djv327. Print 2016 Feb. Review.

PMID:
26546117
16.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators.

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
17.

Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials.

Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, Chlebowski RT.

Breast Cancer Res Treat. 2012 Feb;132(1):275-85. doi: 10.1007/s10549-011-1848-9. Epub 2011 Nov 1.

18.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
20.

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20.

PMID:
16033876

Supplemental Content

Support Center